Fulcrum Therapeutics Strikes All-Stock Merger With Slate Medicines
Fulcrum Therapeutics and Slate Medicines merge in an all-stock deal to develop migraine drugs, backed by a $245M private placement.
Read original at benzingaStocks · News reference
UPDATED: Fulcrum Therapeutics Launches Restructuring Plan Following Discontinuation Of Pociredir For Sickle Cell Disease, Cutting Workforce By 85% From 57 To 9 Employees And Recording ~$4.2M In Restructuring Charges
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Jun 4, 2026, 8:14 PM
- Checked
- Jun 4, 2026, 8:20 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
8-K filing — Fulcrum Therapeutics, Inc. (FULC)
Filed: 2026-08-17 AccNo: 0001193125-26-353278 Size: 15 MB Item 1.01: Entry into a Material Definitive Agreement Item 3.02: Unregistered Sales of Equity Securities Item 5.01: Changes in Control of Registrant Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Read original at edgarFulcrum Therapeutics And Slate Medicines Merge In All-Stock Deal; Combined Company To Operate As Slate Medicines
Combined company to operate as Slate Medicines and focus on advancing Slate's portfolio of next-generation migraine therapeuticsSlate’s lead product candidate, SLTE-1009, is a clinical stage, potentially
Read original at benzinga